ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1472

Primary Sjögren’s Syndrome and Development of Another Connective Tissue Disease During Follow-up

MARIA FLORENCIA Rodriguez1, Anastasia Secco 2, Catalan Pellet 3, natalia herscovich 1, cristina Amitrano 4, Cecilia Asnal 5, Alejandro Nitsche 6, Julia Demarchi 7, damian duartes 8, Francisco Caeiro 9, Veronica Saurit 10, Nadia Riscanevo 11, Silvia Papasidero 12, Carla Gobbi 13, laura raiti 14, vanesa cruzat 14, Lida santiago 15, Sofia Velez 16, Gabriela Salvatierra 17 and Vicente Juarez 18, 1hospital rivadavia, buenos aires, Argentina, 2Hospital Rivadavia, Caba, Buenos Aires, Argentina, 3Rivadavia, CABA, Argentina, 4Hospital Aleman, CABA, Argentina, 5Instituto Centenario, Buenos Aires, Buenos Aires, Argentina, 6Hospital Aleman, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 7Hospital Británico, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 8hospital britanico, buenos aires, Argentina, 9Hospital Privado de Córdoba, Cordoba, Argentina, 10Hospital Privado, Centro Médico de Córdoba, Córdoba, Argentina, Cordoba, Argentina, 11Hospital Privado de Córdoba, Cordoba, Cordoba, Argentina, 12Hospital General de Agudos Dr. E. Tornú, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 13CÁTEDRA DE CLÍNICA MÉDICA I, HOSPITAL CÓRDOBA, FACULTAD DE CIENCIAS MÉDICAS, UNIVERSIDAD NACIONAL DE CÓRDOBA, ARGENTINA, Cordoba, Cordoba, Argentina, 14clinica bessone, buenos aires, Argentina, 15OMI, Ciudad Autonoma de Buenos Aires, Argentina, 16Consultorio Privado S.V, Buenos Aires, Buenos Aires, Argentina, 17IPRI, Santiago del estero, Santiago del Estero, Argentina, 18Hospital Milagros de Salta, Salta, Salta, Argentina

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: another and connective tissue diseases, development, primary sjogren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Sjögrenʼs Syndrome – Basic & Clinical Science Poster II

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Primary Sjögren’s Syndrome (pSS) is a chronic autoimmune disease characterized by lymphocytic infiltration of the exocrine glands. Is the connective tissue disease that is most frequently associated with other autoimmune disorders and approximately 30% of these patients have another associated autoimmune condition. To date, no studies have evaluated the frequency of another autoimmune connective tissue disease development in patients with initial diagnosis of pSS. 
OBJECTIVES: To determine the frequency of patients who, following the diagnosis of pSS, developed another autoimmune rheumatic disease during their follow-up using the GESSAR database (Sjögren Syndrome Study Group of the Argentine Society of Rheumatology). To detail the connective tissue diseases that occurred most frequently in these patients. To describe the clinical, serological and salivary gland histology characteristics of these patients.

Methods: Descriptive, observational, cross-sectional study. We analyzed the data of patients diagnosed with pSS (American-European criteria 2002 / ACR-EULAR 2016), included in the GESSAR database. It was considered the development of another connective tissue autoimmune disease in those cases in which the diagnosis was added during follow-up.

Results: 681 patients were included, mean of following in years was 4.7 años (SD 4.94), 94.8% were women, mean age of 54 (+/- 14) and mean age at diagnosis of 50 (+/- 13) years. Of the total of patients, 30 (4.41%) developed another autoimmune rheumatic disease, according to the classification criteria for each disease, in its evolution. The median time to development was 4 (ICR 2-9). They were: Rheumatoid Arthritis (RA) 14 patients, scleroderma 9 patients, lupus (SLE) 5 patients, dermatomyositis 1 patient and RA plus SLE 1 patient. The mean age of this subgroup was 53 (+/- 14), with a mean age at diagnosis of pSS 48 (+/- 13), 91 % were women. Regarding the SICCA symptoms: 96% reported xerophthalmia, and 86.2% xerostomia to the diagnosis of pSS. With respect to the objective tests: 92% had positive Schirmer test, 88.24% Bengal Rose test or Lisamine Green or positive staining score, 81.2% positive sialometry, Ro + 82.1% and La + 33.33% of patients. Of the 30 patients, 14 had a minor salivary gland biopsy, 12 of them with positive results. Prior to the diagnosis of RA, 78% of the patients presented with arthralgia and arthritis, 12 had RF + and in 2 of the 14 patients the dose of ACPA was recorded and the result was positive. Prior to the diagnosis of scleroderma, 44% of the patients who developed this disease had raynaud’s phenomenon and 22.22% ANA with centromeric pattern, 1 patient with PHT and 3 patients with esophagitis due to reflux. 20% of patients who added SLE also presented raynaud’s phenomenon. 1 patient had anticardiolipin +, 100% reported arthralgia and 80% had arthritis.

Conclusion: Of all the patients analyzed, 4.4% developed another connective tissue disease during their follow-up. We consider the importance of recognizing this possibility in order to arrive at an early diagnosis. The presence of certain clinical and serological manifestations could be considered as suggestive of the subsequent development of another autoimmune rheumatic disease.


Disclosure: M. Rodriguez, None; A. Secco, None; C. Pellet, None; n. herscovich, None; c. Amitrano, None; C. Asnal, None; A. Nitsche, None; J. Demarchi, None; d. duartes, None; F. Caeiro, None; V. Saurit, None; N. Riscanevo, None; S. Papasidero, None; C. Gobbi, None; l. raiti, None; v. cruzat, None; L. santiago, None; S. Velez, None; G. Salvatierra, None; V. Juarez, None.

To cite this abstract in AMA style:

Rodriguez M, Secco A, Pellet C, herscovich n, Amitrano c, Asnal C, Nitsche A, Demarchi J, duartes d, Caeiro F, Saurit V, Riscanevo N, Papasidero S, Gobbi C, raiti l, cruzat v, santiago L, Velez S, Salvatierra G, Juarez V. Primary Sjögren’s Syndrome and Development of Another Connective Tissue Disease During Follow-up [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/primary-sjogrens-syndrome-and-development-of-another-connective-tissue-disease-during-follow-up/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/primary-sjogrens-syndrome-and-development-of-another-connective-tissue-disease-during-follow-up/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology